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Abstract 
 
Background: The aim of this PhD dissertation is to show the development, validation, 
comparison and preliminary clinical implementation of different multigene-based assays for the 
pre-surgical risk stratification of indeterminate thyroid fine-needle aspirates (FNA). In particular, 
this work was focused on the validation and comparison of two commercially multigene assays 
available for the study of the molecular alterations occurring in thyroid neoplasms, and on the 
development of a custom next-generation sequencing genomic panel. Methods: The two 
commercially available assays, one based on a real-time PCR (RT-PCR) technology and one 
based on a next-generation sequencing (NGS) platform were tested on a series of indeterminate 
thyroid FNA. Moreover, a custom NGS gene panel was designed and tested on a different series 
of retrospective and prospective FNA samples. Results: The commercial NGS panel showed 
parametric output data that were not sufficient to reliably use this panel on our clinical routine 
samples. Thus, the RT-PCR assay, which asses BRAF, N-H-KRAS, RET/PTC and PAX8/PPARG 
genomic alterations, were chosen for the subsequent clinical validation on a prospective series of 
n=1172 thyroid FNAs. In order to calculate the pre- and post- test risk of malignancy (ROM), 
only FNA with available histological follow-up (207/1006 adequate FNA, 20.6%) were included 
in the final study. The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was 
adopted for the microscopic diagnosis. FNA classified as atypia of undetermined 
significance/follicular lesion of undetermined significance (AUS/FLUS) showed a 25.9% pre-test 
ROM whereas post-test ROM was 42.6% in mutation-positives (MT-pos) and 14.5% in mutation-
negatives (MT-neg) cases, respectively. Considering the MT-positive cases, the cases harbouring 
BRAF-like mutations (BRAFV600E, RET/PTC1, RET/PTC3)  showed a statistically significant 
higher ROM (80%) than those with RAS-like mutations (N-H-KRAS, PAX8/PPARγ) (32.4%, 
p=0.010). Follicular neoplasm/suspicious for follicular neoplasm (FN/SFN) FNA showed a 44.1% 
pre-test ROM. Conversely, FN/SFN post-test ROM was 80% in MT-pos and 29.1% in MT-neg 
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cases. Although BRAF- and RAS-like mutations were associated to different ROM even in 
FN/SFN cases (100% vs 71.4%), this difference did not reach a statistical significance (p=1,0). 
Suspicious for malignancy (SFM) FNA showed a 93% pre-test ROM; this latter figure almost 
overlapped to post-test ROM of both MT-pos (100%) and MT-neg (84.6%) FNAs. In particular, 
BRAFV600E-mutated FNAs were consistently associated with a papillary carcinoma on 
histology, irrespective of TBSRTC categories. Moreover, in order to switch from a RT-PCR based 
technology, that allows the study of alteration in only 7 genes, to a more comprehensive NGS-
based multigene assay, we designed and analytically tested the performance of a custom panel. 
This latter, include beyond the 7-genes, additional genes which may give an additional predictive 
value when performed on indeterminate thyroid FNAs.  
 Conclusions: Our preliminary data show that the 7-gene RT-PCR based test may 
contribute to the risk stratification in AUS/FLUS and FN/SFN categories, thanks to the significant 
difference in post-test ROM between MT-pos and MT-neg FNAs, confirming the high positive 
predictive value of BRAFV600E and BRAF-like mutations over the RAS-like genomic 
alterations. Moreover, the preliminary results of the custom NGS panel were satisfactory enough 
to expect its effective future adoption on our routine clinical samples. 
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Introduction 
Thyroid carcinoma represents about 1% of all human malignancies (1). On the overall, 4% to 
7% of adults show a palpable thyroid nodules, while in 70% of cases subclinical nodules are 
present (1-2). The main challenge in a patient with a thyroid nodule remains the exclusion of 
malignancy because benign nodular thyroid disease represent the highly prevalent condition. In 
this setting, Fine-Needle Aspiration (FNA) of thyroid nodules is the most accurate and cost-
effective tool with which to evaluate thyroid nodules, coupled with the introduction of the 
Bethesda System for Reporting Thyroid Cytopathology (TBSRTC), a 6-tiered classification 
system which assign different malignancy risk to the morphological features observed in thyroid 
FNA, improving the standardization of cytological diagnosis (Table 1) (3). However, the 
malignancy risk rates associated with the Bethesda diagnostic classes that fall within the 
“indeterminate” categories (namely atypia of undetermined significance/follicular lesion of 
undetermined significance, follicular neoplasm/suspicious for follicular neoplasm, and 
suspicious for malignancy) significantly differ among institutions, thereby leading to ambiguity 
regarding the correct patients management. In this setting, molecular biology may help to 
improve the diagnostic accuracy of indeterminate samples avoiding the patients overtreatment 
when a benign nodules is present, increasing the pre-surgical detection of malignancies (4). 
Patients management guidelines for thyroid nodules suggest that in the case of an indeterminate 
lesion a surgical excision should be necessary, because only histological examination is able to 
make a clear-cut discrimination between benign and malignant lesions (5). To date, none of the 
clinical, imaging, and cytological parameters proved to be able to identify preoperatively the 
patients with "indeterminate" FNAB reports who really may benefit of a surgical approach. In 
order to address and overcome the limitations of cytological examination, many molecular 
biology techniques (e.g., sanger sequencing, pyrosequencing, Real-Time PCR and next 
generation sequencing) evaluating the genetic alteration in the relevant signalling pathway 
associated with the development of thyroid neoplasms (Figure 1) have been implemented or are 
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under evaluation (4-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. The Bethesda System 2017 for reporting Thyroid Cytophatology. 
 
In this setting many laboratory developed tests (LDT) or commercial available kits designed on 
signalling pathways related to the development of thyroid lesions were evaluated. However, the 
increasing understanding of the genetic events involved in thyroid tumorigenesis and 
progression to more aggressive forms, may lead to the identification of more reliable tumour-
specific markers (7). Currently, it is thought that papillary carcinoma and follicular carcinoma 
arise independently of one another, whereas there is limited evidence to suggest a progression 
from follicular adenoma to follicular carcinoma. Figure 1 depicts a summary of the known or 
suspected molecular events that lead to the oncogenesis of papillary carcinoma, follicular 
adenoma and follicular carcinoma, and finally poorly differentiated and anaplastic carcinoma. 
Several molecular mutational alterations have been discovered in thyroid cancer during the last 
three decades (Table 2) (8-9). 
 
Diagnostic category Risk of 
malignancy (%) 
Usual Management 
Non-diagnostic or Unsatisfactory 5-10% Repeat FNA   
Benign 0-3% Clinical and 
sonographic follow-up 
Atypia of Undetermined Significance or 
Follicular Lesion of Undetermined Significance 
(AUS/FLUS) 
10-30% Repeat FNA, 
molecular testing, or 
lobectomy 
Follicular Neoplasm or Suspicious for a Follicular 
neoplasm (FN/SFN) 
25-40% Molecular testing, 
lobectomy 
Suspicious for Malignancy (SFM) 50-75% Near-total 
thyroidectomy or 
lobectomy 
Malignant 97-99% Near-total 
thyroidectomy or 
lobectomy 
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Figure 1. Molecular alterations in thyroid tumors.  
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TABLE 2. Average prevalence of mutations in various types of thyroid cancer. 
 
 
Several groups have determined if genetic mutation analysis can be an useful adjunct technique in 
"indeterminate" cytology diagnoses. Differences in the utility of tests designed to “rule out” and/or 
“rule in” malignancy for indeterminate thyroid fine‐needle aspirations (FNAs) (10). A simplified 
management algorithm is shown for illustrative purposes, in which patients with cytologically benign 
nodules are followed clinically, those with cytologically malignant nodules undergo total 
thyroidectomy, and patients with cytologically indeterminate nodules undergo further testing (11). 
Nikiforov et al. recently conducted a prospective study to assess the significance of testing a panel of 
tumor-specific mutations to improve the preoperative diagnosis of a thyroid nodule (1). Residual 
material from 1056 consecutive thyroid FNAB samples with indeterminate cytology was used for 
prospective molecular analysis consisted of BRAF V600E, RAS, RET/PTC, and PAX8/PPARγ 
rearrangements. The authors reported that these events were highly specific for detecting malignancy 
but less sensitive, mainly in nodules classified as "indeterminate". In this category, in fact, the detection 
of any mutation conferred the risk of malignancy of 88%, while the risk of cancer in mutation-negative 
nodules was 6% (13). 
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Figure 2. Molecular cytopathology for thyroid nodules: (A) Tests optimized to “rule out” malignancy have a high 
negative predictive value (NPV) a negative (defined as “benign”) result indicates a low cancer risk, triaging a patient to 
active surveillance and reducing the rate of lobectomies performed for benign nodules. For tests with a low positive 
predictive value (PPV), a positive (defined as“suspicious”) result indicates an indeterminate risk of cancer and the 
consideration of diagnostic lobectomy; patients with nodules with benign histology require only clinical follow‐up, 
whereas those with malignant histology may require a completion thyroidectomy. (B) Tests optimized to “rule in” 
malignancy such as the 7‐gene mutation/fusion panel have a high PPV; a positive test result can direct patients to 
undergo total thyroidectomy upfront, sparing patients the need to return to the operating room for a completion 
thyroidectomy. A negative test result can not exclude malignancy due to the low NPV, and a diagnostic lobectomy 
would be advised. (C) The ideal molecular test for patients with cytologically indeterminate thyroid nodules should 
have a sufficiently high NPV and PPV so that a negative result can safely direct patients to watchful waiting and a 
positive result can direct patients to a total thyroidectomy, thereby reducing the need for a diagnostic lobectomy 
(indicated by the dotted lines). In the future, management algorithms may consider lobectomy to be appropriate and 
sufficient management for patients with nodules with molecular signatures suggestive of a noninvasive follicular 
variant of papillary carcinoma (indicated by the asterisk). Modified from Nishino et.al (29). 
 
In a literature review by Filicori et al. was established that a mutation analysis model using the 
prevalence of BRAF, RET, RAS, and PAX8/PPARγ mutations to refine "indeterminate" lesions 
diagnosis. This model was applied retrospectively to a study cohort of 466 consecutive 
"indeterminate" lesions that underwent hemi- or total thyroidectomy for definitive diagnosis, to 
evaluate its accuracy for identifying malignancy. Out of 466 "indeterminate lesions" in the 
study, 30% were malignant. These included 66 cases of papillary carcinoma, 45 cases of 
follicular variant of papillary carcinoma, 18 cases of follicular carcinoma, and 10 others. The 
mutation analysis model would correctly identify only 48 of 139 (34%) of malignant 
"indeterminate" lesions. Therefore, when mutation analysis is negative, the overall risk of 
malignancy would be 23%. "Indeterminate" lesions with a negative mutation analysis still carry 
a significant risk of malignancy, requiring surgery for definitive diagnosis (14). Although these 
data seem to suggest that genetic approach has low sensitivity for "indeterminate" nodules, the 
preoperative detection of these mutations, particularly for BRAF mutation, may help to identify 
patients at high risk of recurrence and death (14). 
In the past, in relation to the narrow spectrum of genetic alterations analyzed, single gene 
techniques, such as Sanger Sequencing or Real - Time Based (RT-PCR) approach were largely 
used in many molecular biology laboratories (15). However, after data with the Human Genome 
Project were obtained, the need to obtain ore genetic information in clinical practice increase 
tremendously, leading to the introduction in routine setting of multiplex molecular biology 
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techniques, e.g.  Matrix Adsorption Laser Diode Mass Spectrometry (MALDI) evaluation Time 
of Fly (TOF) of different nucleic acids and, most important, the Massive and Parallel 
sequencing approach, also known as Next Generation Sequencing (NGS) (16). Several NGS 
panels evaluating different genes regions are commercially available but these panels often 
contain genes or hotspots that are not of particular interest for molecular diagnostics of thyroid 
neoplasms (17).  
Considering all together the data discussed, an important research hot – topic to improve the 
classification of thyroid lesions is represented by the application of new molecular biology 
techniques to analyse the clinical relevant gene alterations, starting from cytological samples 
derived nucleic acids, to develop an integrated morpho – molecular approach leading to better 
define the patients clinical management. 
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Aims of this study 
 The aim of this PhD thesis is to show the development, validation, comparison and 
clinical implementation of different multigene assays for the pre-surgical risk stratification of 
indeterminate thyroid fine needle aspirations. In particular, during these three PhD course years,  
I was actively involved in the validation and implementation in clinical practice of a commercial 
RT – PCR based assay to study the molecular alterations in 7 different genes (BRAF, KRAS, 
NRAS, HRAS, RET/PTC1, RET/PTC3 and PAX8/PPARγ) in order to further stratify the risk of 
malignancy (ROM) on a prospective series of n=1156 thyroid FNA. 
 The second aim of this PhD thesis is to show the preliminary results obtained from the 
NGS testing of thyroid cytological samples, by using both a commercial (Comprehensive 
Thyroid and Lung - Archer) and in-house developed custom NGS panel, specifically targeting 
the genes involved in thyroid oncogenesis. 
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Chapter 1:  
Validation and implementation in clinical practice of a 
commercial 7 genes RT – PCR based assay. 
 
1.1 Material and Methods: 
 
On the overall, n=1172 FNA were analyzed. In particular n= 755 cases were classified as Atypia 
of Undetermined Significance or Follicular Lesion of Undetermined Significance (AUS/FLUS), 
n=140 cases were classified as Follicular Neoplasm or Suspicious for a Follicular neoplasm 
(FN/SFN), n=111 cases were classified as Suspicious for Malignancy (SM), n=166 were 
classified as Malignant (M). 
Total cases 1172 
AUS/FLUS 755 
FN/SFN 140 
SM 111 
M 166 
 
Table 3. TBSRTC of analyzed FNA. 
 
From all the selected sample DNA and RNA was simultaneously extracted from each selected 
slide by using the DNA/RNA All Prep Mini Kit (Qiagen, Hilden, Germany) with a modified 
protocol, adapted for cytological specimens. The evaluation of nucleic acids concentration was 
obtained for each sample by using the TapeStation System (Agilent Technologies, Santa Clara, 
California, USA) with a dedicated software (TapeStation 4200 suite). 
 
1.1.1 DNA and RNA Extraction. 
The nucleic acids were extracted using ALL PREP DNA / RNA mini kits (Qiagen GmbH, Hilden, 
Germany) according to a modified version of the manufacturer's protocol. In particular, the 
  
14  
protocol developed consist of the following steps: 
1. add 350 µl of RLT in the sample; 
2. Pipette 5 times and vortex for 1 m and spin; 
3. Transfer everything to a DNA column for ALL Prep (white cap with lilac ring);  
4. Centrifuge for 30 seconds x 13000 rpm and then transfer the column into a new 2 ml tube and 
store at 4 °; 
5. the eluate for RNA extraction and proteins was stored at – 80°C; 
6. Add 250 µl of 100% ethanol directly and pipette 5 times (do not centrifuge and do not 
flicker); 
7. Transfer 700 µl to the RNAsi Spin Column and centrifuge 30 seconds x 13000 rpm; take the 
eluate and transfer it to a 1.5 tube; 
8. Store at 4 ° (it will contain the PROTEINS); 
For RNA purification: 
1. By using the dedicated column a 2 ml tube was mounted again (it will contain the column 
with the membrane with the RNA); 
2.  Add 700 µl of RW1 to the spin column and centrifuge for 30 seconds at 13,000 rpm.  
3. Discard the sub-matrix ONLY NOW, because now contain nothing. 
4. Add 500 µl of RPE to wash and purify RNA, centrifuge for 30 seconds at 13,000 rpm and 
discard the sub-matrix and reassemble the column;  
5. Repeat the same step with RPE and then transfer the tube in a new 1.5ml tube for the elution 
in 35 µl of RNasi Free Water.  
6. Store the samples at – 20°C until a processing.  
For DNA purification: 
1. Proceed with the sample purification by using two different buffer: AW1 and AW2; 
2.  Transfer the tube in a new 1.5 ml tube for the elution in 35 µl of DNasi Free Water. 
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Figure 3. Schematic representation of DNA/RNA extraction protocol from the sample to the storage at -20°C. 
 
The quantity and quality of DNA was evaluated using a capillary electrophoresis TapeStation 
(Agilent Technologies, Santa Clara, California, USA ). In addition, the amount of RNA was also  
evaluated using a spectrophotometer (NanoDrop, Thermo Scientific, Milan, Italy) and the 
absorbance values at 260/280 were used to evaluate the purity, in terms of protein contamination, 
while the values 260/230 absorbance materials have been used to verify the purity. 
 
1.1.2 Real-Time PCR.  
The amplification reaction for DNA and RNA was performed using the Thyroid Cancer Mutation 
Analysis and Fusion Gene Detection kit (Entrogen Woodland Hills, CA 91367, USA) (18). The 
kit includes the use of TaqMan probes and 8 different mixes to detect different mutations in 7 
genes that play a fundamental role in thyroid classification. The Kit reference range is as follows: 
BRAF (V600E); KRAS (G12A, G12D, G12R, G12V, G13D, G12C, G12S); NRAS (Q61H: CAC, 
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CAT), Q61L, Q61K, Q61R; HRAS (G12V, G13R, Q61R); RET / PTC1; RET / PTC3; PAX8 / 
PPARƔ. 
Following the tests for the technical validation of the kit, the reaction mix was optimized in a final 
volume of 15 μl for the DNA and 12.5 μl for the RNA. In particular, the DNA mix consists of 2X 
PCR reaction mix, Primer Mix, nuclease free water and 2 μl sample at a concentration of 2.5 
ng/μl. As for the RNA mix, this is composed of 5X enzyme mix, Primer Mix, Manganese Acetate, 
nuclease free water and 2.5 μl sample at a concentration of 2 ng/μl. The amplification reactions 
were set up in duplicate on 384-well plates and ran on Quant Studio 5 Real-Time (Life 
Technologies, Massachusetts, USA). For DNA the following thermal protocol was used: 1 cycle 
at 95 ° C for 10 min; 40 cycles at 95 ° C for 15 seconds and 40 cycles at 60 ° C for 1 min; the 
temperature increase from 60 to 95 ° C is 0.1 ° C per second. For RNA, the kit provides a single 
step of reverse transcription and amplification and the reaction is subject to the following thermal 
protocol: 1 cycle at 55 ° C for 5 min; 1 cycle at 60 ° C for 5 minutes; 1 cycle at 65 ° C for 5 
minutes; 40 cycles at 95 ° C for 10 seconds and 40 cycles at 60 ° C for 45 seconds; the 
temperature increase from 60 to 95 ° C is 0.1 ° C per second. The results obtained were analyzed 
using the QuantStudio Design & Analysis software (Lifetechnologies, Massachusetts, USA). 
 
1.1.3 Analysis of sensitivity and specificity. 
Before the implementation of the Thyroid Cancer Mutation Analysis and Fusion Gene Detection 
kit (Entrogen Woodland Hills, CA 91367, USA) in clinical practice, we evaluated the analytical 
sensitivity and specificity by using a sample set previously tested by a validated Next Generation 
Sequencing panel. In particular, n = 1 BRAF V600E; = 1 KRAS G12D; n = 1 NRAS Q61H and n = 
1 wild - type samples were selected basing on the reference range reported by the manufacturer of 
Thyroid Cancer Mutation Analysis and Fusion Gene Detection kit. In particular, for each sample, 
three dilution points of the mutated allele were prepared: 10%, 5% and 1%, to evaluate the limit 
of detection (LOD) for the selected mutations. Furthermore, to evaluate the reproducibility, the 
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reported experiment was repeated twice in two different time from two different operators. 
 
1.2 Data Interpretation 
RT-PCR was feasible in the majority of cases (1069 of 1172 cases; 91.2%); only n=103 cases 
(8.8%) were failed. In particular, n=10 (0.8%) were completely failed samples, conversely n=2 
cases are failed in the amplification for DNA while, in majority of cases, n=91 were failed on 
amplification for RNA. The mean and median DNA yields of the successfully processed samples 
were 8.75 ng/µl and for RNA 2.92 ng/µl, respectively (range, 0.0281-60 ng/µl for DNA, while for 
RNA range were 0.1-36.3 ng/µl). It is interesting to note that in the majority of  processed 
samples (75.7%) featured suboptimal DNA and RNA material was classified as AUS/FLUS. 
 
1.3 Results 
1.3.1 Molecular Analysis 
BRAF, RAS, RET and PAX8/PPARγ somatic variants were identified in 88 of 1069 samples. In 
particular in the category of AUS/FLUS (n=116/1069 we have found n=47 MT and n=58 WT. In 
the FN/SFN category (n=34/1069) we have found n=10 MT and 22 WT, while in the SFM 
category (n=57/1069), the mutation rate was n=31 MT and n=21 WT (Table 4). 
 
 BRAF HRAS NRAS KRAS RET/PTC PAX8/PPARγ WT INADEQUATE 
AUS/FLUS 10 14 18 1 1 3 58 11 
FN/SFN 3 2 5 0 0 0 22 2 
SFM 28 0 3 0 0 0 21 5 
 
Table 4. Distribution of gene mutations in relation to samples classification. 
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1.3.2 Clinical interpretation 
Our preliminary data show that the 7-gene RT-PCR based test may contribute to the risk 
stratification in AUS/FLUS and FN/SFN categories, thanks to the significant difference in post-
test ROM between MT-pos and MT-neg FNAs, confirming the high positive predictive value of 
BRAFV600E and BRAF-like mutations over the RAS-like genomic alterations.  
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Chapter 2: 
Performance evaluation of Archer- Comprehensive Thyroid 
and Lung (CTL) NGS Panel. 
 
 
2.1  Materials and Methods: 
Touch imprint cytology is a well known rapid histopathological method of intraoperative analysis 
of biopsy specimens and allows the extraction of good quality and quantity DNA and RNA 
respect to conventional cytological and histological samples. To preliminary investigate the 
performance of Archer- Comprehensive Thyroid and Lung (CTL) Panel a serie of n. 8 touch 
imprint was produced from eight different fresh thyroid tissues. In particular n.6 samples showed 
an histological diagnosis of Papillary Thyroid Carcinoma (PTC), n. 2 samples were diagnosed as 
follicular variant of PTC. (Table 5) 
 
# ID Bethesda System Histology 
1 18/9598 Malignant PTC 
2 18/3561 Suspicious for Malignancy PTC 
3 18/10633 Suspicious for Malignancy fvPTC 
4 18/8786 Suspicious for Malignancy fvPTC 
5 18/6951 Malignant PTC 
6 18/7691 Malignant PTC 
7 18/7887 Follicular Neoplasm or Suspicious for a Follicular Neoplasm PTC 
8 18/19142 Malignant PTC 
  
Table 5. Sample set selected to produce the touch imprints. 
 
DNA and RNA were simultaneously extracted from each touch imprint following the previously 
reported adapted protocol and the quantity and quality of extracted nucleic acids were assessed by 
using TapeStation 4200 platform (Agilent Technologies, Santa Clara, California, USA) as 
previously described (section 1.1.1). In addition, each DNA and RNA was analyzed by our 
standard RT - PCR procedure by using the Thyroid Cancer Mutation Analysis and Fusion Gene 
Detection kit. 
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2.1.1 Archer FusionPlex Comprehensive Thyroid and Lung NGS Kit (CTL). 
The Archer® FusionPlex® Comprehensive Thyroid and Lung (CTL) Kit is a targeted NGS panel 
designed to detect gene fusions, SNV, indels, splicing and gene expression in 36 genes (Table 6) 
associated with lung and thyroid cancers (19). 
 
AKT1  PPARγ  IDH1  ERBB2  BRAF  RET  NTRK2  
DDR2  TTF1  NRAS  IDH2  FGFR1  CALCA  ROS1  
HRAS  ALK  PTH  NRG1  KRAS  FGFR2  CCND1  
MET  EGFR  AXL  RAF1  NTRK1  KRT20  FGFR3  
KRT7  NTRK3  SLC5A5  THADA  CTNNB1  GNAS  MAP2K1  
PIK3CA  TTF1  
Legend: 
•  SNV/Indel 
•  Expression 
•  Fusion, splicing or exon-skipping 
Table 6. Gene list covered by Archer® FusionPlex® Comprehensive Thyroid and Lung 
 
2.1.2 cDNA preparation 
cDNA was produced by using a random examer primer mix starting from 20 ng of extracted 
RNA. in a 20 µL mix for each sample. The retrotrascription of RNA into cDNA was obtained by 
using an incubation at 65°C for 5 min followed by a storage at 4°C. To obtain a second strand of 
cDNA produced in the first reaction, a second 20 μL mix was prepared for each sample adding a 
new set of random examer primers. the thermal condition to obtain a second cDNA strand were as 
follow: 25°C for 10 min; 42°C for 30 min; 80°C for 20, with a final step at 4°C. The ends of 
synthesized cDNA were repaired by using the End Repair mix (Archer) following the 
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manufacturer's instructions with an incubation of 25°C for 30 min. After the end repair process, 
the full constructed cDNA were cleanup with the Agencourt AMPure Beads (Beckman Coulter, 
Brea, California, USA) by using a standard protocol. The prepared full constructed and purified 
cDNAs were assessed by using PreSeq RNA QC assay protocol. 
  
2.1.3 PreSeq RNA QC assay. 
 
To evaluate the amplifiability of produced cDNA, we prepare qPCR reaction mix for duplicate 
analysis of each diluted cDNA sample and one No Template Control (NTC) made from 10 µL 
Ultra-Pure Water, for quantified and control the RNA that then following the Archer protocol 
according to the manufacturer's instructions. Six microliters of the reaction mix were added into 
each assigned well of a qPCR plate/tube, then 4μL of the diluted cDNA samples or NTC into 
assigned wells/tubes containing reaction mix were added. The prepared mix was slowly vortexed 
to avoid introducing bubbles. Prepared reactions were amplified  following the reported thermal 
conditions (Table 7) : 
 
 
Table 7. Thermal conditions for libraries preparation for the Archer FusionPlex Comprehensive Thyroid and Lung 
panel. 
 
The samples showing a Cycle Threshold (Ct) within 28 were considered adequate for library 
preparation.  
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2.1.4 Library Preparation and Sequencing 
The libraries were prepared following the Archer Fusion Plex Protocol adapted for Ion Torrent 
platforms, by using specific Archer barcode set (MBC Adapter) with a two step PCR 
amplification process (one conventional PCR and one emulsion PCR). In particular, barcoded 
libraries were combined in a pooled library for manual template preparation by emulsion PCR on 
the Ion OneTouch 2 system (Thermo Fisher Scientific). The pooled library concentration was 
increased from the 2 µl suggested by the manufacturer to 6 µl to obtain a higher number of 
charged ion sphere particles without having an unacceptable rate of polyclonal reads. The 
template ion sphere particles were enriched and the sequencing primers and polymerase were 
added, loaded on 316 chips, and sequenced on the PGM sequencer with the Ion PGM Sequencing 
200 Kit v2 (Thermo Fisher Scientific), according to the manufacturer’s instructions.  
 
 
2.2 Data interpretation. 
 
Data analysis and interpretation were based on the Ion Torrent Suite Software V.5.0.3 
(ThermoFisher Scientific) workflow by using the hg19 human as a reference genome, the 
RNAseq plugin (version 5.0.3.5) was applied for the automatic variant annotation. In addition, 
BAM files were used for visual inspection by using the Golden Helix Genome Browser (version 
2.0.7;Golden Helix Inc, Bozeman, Mont), and only the mutations reported in the COSMIC 
database  (http://cancer.san-er.ac.uk/) were taken into account. Post sequencing metrics (number 
of mapped reads, the average base depth, the percentage of on-target reads, and uniformity were 
recorded for each sample. No minimal parametric thresholds were considered and all variant calls 
occurring in the relevant thyroid genes underwent verification by Real-Time. 
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2.3 Results. 
RNA quantity and Quality: 
TapeStation 4200 platform was used to assess the quantity and quality of RNA extracted from 
touch imprints. The results are reported in the following table (Table 8):  
 
ID Quantity ng/µl RIN 
1 38.7 3.8 
2 12.6 4.0 
3 41.5 3.8 
4 10.2 4.2 
5 34.8 4.6 
6 58 4.0 
7 2.5 3.8 
8 1.35 3.8 
 
Table 8. Quantity and quality evaluation of sample by TapeStation. 
The assessment of RNA integrity is a critical first step in obtaining meaningful gene expression data. Using intact RNA 
is a key element for successful RT-PCR analyses or other technologies . 
 
2.3.1 PreSeq RNA QC assay. 
RT - PCR Sybr Green (Biorad) based approach on QuantStudio 5 instrument (Thermofisher) was 
used to evaluate the amplifiability of cDNA obtained starting from 20ng of extracted RNA. A Ct 
value within 28 cycle was considered as adequate to proceed with library preparation. The 
obtained results were reported in the following Table 9 and Figure 5: 
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# ID [ ng/µl] Ct value bp [Library pg/µl] 
1 9598 38,7 26,62 276 4770 
2 3561 12,6 29,952 222 4800 
3 10633 41,5 31,639 157 9230 
4 8766 10,2 28,583 228 4130 
5 6951 34,8 29,618 230 4220 
6 7691 58 29,313 244 5580 
7 7887 2,5 19,293 X X 
8 19142 1,35 21,111 X X 
 
 
Table 9. Ct value obtained by using RT - PCR Syber Green based assay to evaluate the quality of cDNA obtained 
from the reverse transcription of touch imprints derived RNA. 
 
 
 
Figure 4. the amplification plots (A - H) obtained from cDNA evaluation by using SyberGreen on QuantStudio 5 
instrument and analyzed with QuantStudio Cloud Software are reported. For each amplification plot, on y axis are 
reported the Relative Fluorescence Unit (Rfu) reached during the amplification process and on x axis are reported the 
PCR cycles. 
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2.3.2 Library preparation and Sequencing. 
Basing on the data obtained by PreSeq RNA QC assay, only n. 6 samples were able to proceed 
with the library preparation step. In accordance with the aim of our project, we decide to proceed 
with all samples to the libraries preparation to evaluate the performance of the 
Archer® FusionPlex® Comprehensive Thyroid and Lung (CTL) Kit  also on suboptimal RNA 
samples that represent a more closed samples respect to cytological one. All the libraries were 
quantified and qualified by using High Sensitivity DNA assay on Tape Station 4200 platform and 
the results were reported in the following Figure 6: 
 
 
Figure 5. Quantification and Qualification results obtained for each libraries produced starting from 
cDNA constructed by using 20 ng touch imprint derived RNA. The electropherogram ( A - H) report the 
length spectrum of cDNA libraries fragments and relative quantity. The electropherogram from A to F 
represents adequate library spectrum, while the results report in electropherogram G and H show an 
absence of an adequate libraries production. 
 
Basing on the results obtained from Tape Station 4200 analysis, sample number 7 (Panel G - 
Figure 5) and sample number 8 (Panel H - Figure H) were excluded from pooled library to 
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proceed with  the emulsion PCR for the clonal amplification of cDNA fragments. The pellet 
recovered form OneTouch recovery tube (thermofisher) was prepared for sequencing, as 
described in the materials and methods section (section 2.3.2) and the result obtained are 
summarized in Table 10 and Figure 7. 
 
ISP Summury 
708.588 Total reads 
82% Loading 5,192,328                           18% Empty Wells 
100% Enrichment 5,169,418 0% No Template 
54% Clonal 2,815,335 46% Polyclonal 
25% Final Library 708,588 0% Test Fragments 
0% Adapter Dimer 
75% Low Quality 
Table 10. Ion Sphere Particles Summary Data 
 
 
 
Figure 6.This are the run summary for the PGM. 
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On the overall, only 2 library were adequately produced and analyzed by using  RNASeqAnalysis 
plugin. The obtained report, contained analytical performance parameters and detected variants, 
was reported below: 
 
 
 
Figure 7. RNA seq analyses by using Torrent Suite with RNA seq Plug-in v.5.0 (Thermofisher). 
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¼ 
Chapter 3:  
Design, development and validation of custom NGS panel for 
our routine setting: NexThyro. 
 
3.1  Materials and Methods: 
 
We developed a custom panel to screen hotspots in 9 genes (7 gene and 2 translocations) for 
clinically relevant mutations in thyroid nodules, as well is in other solid tumor types. Our 
selection was based on information retrieved from COSMIC and by literature. Key factors 
determining our gene selection were 1) the present or likely future clinical significance in terms of 
therapeutic, prognostic or diagnostic value, both from clinical research and pre-clinical data; 2) 
the frequency of known hotspot mutations within the types of tumors predominantly screened in 
our laboratory; and 3) the cost per sample, taking into account the number of samples weekly 
screened and the desired depth of coverage to allow for sufficient sensitivity. We found that the 
resulting total size of 8 kb is a feasible compromise, offering a sufficiently extensive and 
clinically relevant mutational profiling in a cost-efficient way. 
Here, we describe the design, development and performance evaluation of a custom NGS targeted 
panel for thyroid cancer. 
 
3.1.1 Design NexThyro panel.  
The Ion AmpliSeq  Designer  suite  v5.3.1 with hg19 was used as reference genome to develop a 
customized fusion panel targeting 9 gene (BRAF,  RET,  NRAS, HRAS, KRAS, TERT and 
GNAS, RET/PTC and PAX8/PPARγ) (Tables 11 - 12)  that are associated with prognosis of 
patients.  
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Gene chr 
BRAF chr7 
[ex.11;ex.15] 
RET chr10 
[ex10; 11; 13; 15; 16] 
NRAS chr1 
[ex2; 3; 4] 
HRAS chr11 
[ex2;3] 
KRAS chr12 
[ex2; 3; 4] 
TERT chr5 
[ex2;3;4;5;6;7;8;9;10;11;12;13;14;15] 
GNAS chr20 
[ex8;9] 
 
Table 11. The table reported the gene that are investigated with the our custom panel “NexThyro”. 
This genes have an importance in the carcinogenesis of thyroid tumor. 
 
 
 
Fusion Pair 
AFAP1-RET 
AKAP13-RET 
CCDC6-RET 
CUX1-RET 
ERC1-RET 
ERC1_ELKS-RET 
FKBP15-RET 
GOLGA5_PTC5-RET 
HOOK3-RET 
KIAA1468-RET 
KIF5B-RET 
KTN1-RET 
NCOA4-RET 
PARG-RET 
PAX8-PPARG 
PCM1-RET 
PCM1_PTC4-RET 
PRKAR1A-RET 
RET-NCOA4 
RET-TRIM33 
TBL1XR1-RET 
TRIM24-RET 
TRIM24_PTC6-RET 
TRIM27-RET 
TRIM33-RET 
TRIM33_PTC7-RET 
 
Table 12. In this table are reported the thyroid translocation that are important in the tumor pathway.  
 
 
A  double  primer pool leading to the selection of, for the first, 31  amplicons  (ranging  from  
125  to  175 bp) and for the second, 30 amplicons for DNA, and for the RNA, always a double 
pool of primers was selected for the panel, the first 17 transcripts, and the second pool, 49 
transcripts,  enabled us  to  cover  all  COSMIC  annotated  mutations  
(https://cancer.sanger.ac.uk/cosmic) in the selected exons of the target genes. The amplicon 
design covering 8kb of genomic DNA was optimized for the simultaneous analysis of 8 samples 
(simultaneously DNA and RNA of the same patients) with the 316v2 chip (Thermofisher, Foster 
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City, CA, USA) on a Personal Genome Machine Torrent (Thermofisher). The panel 
performance was evaluated in different steps: the analytical sensitivity of the assay was assessed 
on DNA from two cell lines and by using an artificial reference standard with multiple 
mutations in different genes. Second, clinical sensitivity and specificity was determined using 
archival DNA and RNA from 16 patients ( 2 set of 8 patients), previously genotyped with a RT-
PCR.  
 
3.1.2 Library Preparation. 
The library was prepared using the Ion AmpliSeq Library Kit 2.0-96LV (Life Technologies) and 
NexThyro primer pools. Any modifications of the manufacturer’s protocol were previously 
assessed on a pre-study sample set of 16 thyroid FNA specimens with characteristics similar to 
those of the FNA samples included in the final study. Barcoded libraries were prepared as 
indicated in the manual kit procedure (ie, with a maximum requirement of 6 µl of DNA extracted 
from any FNA sample). Thus, the minimum DNA concentration required to obtain 10 ng of total 
DNA input was 1.6 ng/µl. In the case of samples containing a low amount of DNA (DNA<1.6 
ng/µl), the DNA was not diluted further and the quantity of nuclease-free water was reduced 
accordingly. The number of multiplex polymerase chain reactions (PCRs) was increased from the 
suggested 20 cycles to 26 cycles, similarly to previous studies (20). Each library was barcoded 
with the Ion Xpress Barcode Adapters 1-16 Kit (Thermo Fisher Scientific Inc), quantified using 
the Qubit photometer and the Qubit dsDNA HS (High Sensitivity) Assay Kit (both Life 
Technologies), and diluted in nuclease-free water to obtain a final concentration of 100 µM.  
 
3.1.3 Emulsion PCR. 
Sixteen barcoded libraries were combined in a pooled library for manual template preparation by 
emulsion PCR (emPCR) on the Ion OneTouch 2 system (Life Technologies). The pooled library 
concentration was increased from the manufacturer suggested 2 μl to 6 μl to obtain a higher 
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number of charged ion sphere particles (ISP) without having an unacceptable rate of polyclonal 
reads (data not shown). As previously described (21), the template ISPs were enriched, and the 
sequencing primers and polymerase were added, loaded on 316 chips and sequenced on the PGM 
sequencer with the Ion PGM Sequencing 200 Kit (Life Technologies), according to the 
manufacturer’s instructions. 
 
3.2 Data Analysis. 
Signal processing and base calling were carried out using the default base-caller parameters on 
Torrent Suite [v.5.0.2] and coverage analysis was performed using NexThyro designed bed files 
with coverage plug-in (v.5.0.2.0). BAM files were visually inspected with the Golden Helix 
Genome Browser v.2.0.7 (Bozeman,MT,USA). Variants were automatically annotated using 
variant caller plug-in (v.5.0.2.1) at specific optimized parameters of the NexThyro panel. In 
particular, only variants with 5X allele coverage and a quality score 20X, within an amplicon that 
covered at least 500X alleles, were called. 
 
3.3 Results. 
3.3.1 Sequencing Performance. 
The experiments carried out on serial dilutions (10%; 5%; 1%) of mutated (BRAF V600E and 
RET – PTC1) cell lines derived nucleic acid showed an a limit of detection of 1% (data not 
reported) for both DNA and RNA NexThyro primers pool. 
We have analyze n= 16 samples for the DNA and n=16 samples for the RNA, in two different 
NGS run. As reported in the Material and Methods section, the NGS analysed samples were 
previously tested on the Real-Time and, in particular, n= 7 samples classified as AUS/FLUS, n= 
2 samples classified as FN/SFN and n= 6 samples classified as Malignant showing a specific 
mutation pattern (reported in Table 13) were processed by using NexThyro panel. 
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The mean and median library yields of the successfully processed samples were 34.4 ng/µl 
respectively (range, < 0.5 - 109 ng/µl). Only n=4 samples were suboptimal to proceed at 
sequencing. The samples characteristics and the analytical results obtained were reported (Table 
13):  
 
Table 13: The table reported the quantity of the library quantified with the fluorometer Qubit (Thermo 
Fisher Scientific Waltham, Massachusetts, Stati Uniti). The Bethesda Classification for each samples and the 
molecular diagnosis after the sequencing was also reported. 
 
Regarding the second NGS run, we analyzed n= 2 samples classified as FN/SFN, n=4  samples 
that were classified as SFM  and n= 8 samples classified as Malignant (Table 14) previously 
assessed by using our validated RT – PCR approach (RT – PCR mutational status was reported 
in Table 14). 
The mean and median library yields of the successfully processed samples were 33.3 ng/µl 
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respectively (range, < 0.5 - 106 ng/µl). Only n=4 samples were suboptimal to proceed at 
sequencing. The results obtained were reported in the following Table (Table 14): 
 
 
 
Table 14: The table reported the quantity of the library quantified with the fluorometer Qubit (Thermo 
Fisher Scientific Waltham, Massachusetts, Stati Uniti). 
The Bethesda Classification for each samples and the molecular diagnosis after the sequencing. 
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Discussion and Conclusions: 
 
The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) lead to an improvement in 
the reproducibility of the FNA diagnosis of thyroid nodules enabling the cytologists to 
recommend a clinical follow-up or a surgical approach according to the ROM of each TBSRTC 
class (22). However, basing only on morphology, up to 30% of thyroid FNA samples are 
classified as indeterminate (1-2). In relation to different experiences, various diagnoses are 
included in the indeterminate category: AUS/FLUS and follicular neoplasm/ suspicious for 
follicular neoplasm (FN/SFN) only or AUS/ FLUS and FN/SFN plus the suspicious for 
malignancy (SM) diagnostic category. The FN/SFN and SM diagnostic classes have intermediate 
(15%-30%) to high ROMs (60%-75%) that warrant diagnostic lobectomy in the former case and 
oncologic thyroidectomy in the latter case (3-4). In particular, AUS/FLUS includes low-risk cases 
that could be managed with follow-up plus FNA repetition as recommended by TBSRTC (23). 
The implementation of molecular techniques could be useful to further stratify the malignancy 
risk of the indeterminate FNAs. As showed by our results, the 7-gene test may be useful to refine 
at least FNA diagnoses as AUS/FLUS and FN/SFN (7). However, despite the high specificity of 
BRAFV600E and RET/PTC as markers of malignancy, the clinical usefulness of the 7-gene test is 
limited by the low specificity and low positive predictive value of RAS and RAS-like mutations 
(PAX8/PPARγ and BRAFK601E) because these mutations are also detected in such benign thyroid 
nodules as follicular adenomas (24). In addition, the indolent encapsulated PTC follicular variant 
recently reclassified as a low-risk neoplasm (non-invasive follicular thyroid neoplasm with 
papillary-like nuclear features [NIFTP]) accounts for a large proportion of RAS-mutated nodules 
(25). However, it remains to be established whether mutation-positive adenomas and NIFTP are 
follicular-patterned in situ carcinomas and should be considered as true-positives in the evaluation 
of the positive predictive value of the 7-gene test. To evaluate the potential impact of NIFTP on 
this series, we reviewed the available histology of benign samples originally classified as 
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follicular adenomas, but none of them met the criteria for an NIFTP diagnosis (26). 
Unfortunately, surgical follow-up was available only for a limited number of patients. In fact, at 
our institution, we have a facility dedicated to the ultrasound-guided FNA of thyroid nodules that 
serves patients referred from a different part of South Italy (27). However, not all patients with a 
cytological or molecular diagnosis (e.g. BRAFV600E) that recommends a surgical approach 
choose to be treated at our institution (eg, patients may prefer private/community hospitals near 
them) (28). We argue that these patients underwent surgery outside our institution, and we were 
not able to correlate the molecular findings with the histological outcomes. This represents a 
limitation of our study, although it reflects our local practice.  
 
To overcome the limitations of the 7-gene test to improve the clinical management of these 
patients a pilot study aiming to evaluate the performance of NGS to extend the number of genes 
investigated simultaneously for each patients starting from cytological samples derived nucleic 
acids was conducted. In particular, as a first step, a commercially available NGS panel (Archer- 
Comprehensive Thyroid and Lung Panel) designed to cover 37 genes (Table 6) starting only 
from RNA was evaluated on a series of n. 8 touch imprint produced from eight different fresh 
thyroid tissues. In particular n.6 samples showed an histological diagnosis of Papillary Thyroid 
Carcinoma (PTC), n. 2 samples were diagnosed as follicular variant of PTC. Touch imprint 
cytology is a well known rapid histopathological method of intraoperative analysis of biopsy 
specimens and allows the extraction of good quality and quantity DNA and RNA respect to 
conventional cytological and histological samples. However, by using this approach, only 2 
samples (2/8; 25%) results adequate for sequencing data analysis. Considering the low 
performance obtained by using this Archer- Comprehensive Thyroid and Lung Panel, a custom 
NGS panel (NexThyro) covering 9 ((BRAF,  RET,  NRAS, HRAS, KRAS, TERT and GNAS, 
RET/PTC and PAX8/PPARγ) (Tables 11 - 12)  was designed and developed in combination with 
dedicated bed files to analyse the sequencing data obtained starting from low DNA and RNA 
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quantity. In particular, a  double  primer pool leading to the selection of, for the first, 31  
amplicons  (ranging  from  125  to  175 bp) and for the second, 30 amplicons for DNA, and for 
the RNA, always a double pool of primers was selected for the panel, the first 17 transcripts, and 
the second pool, 49 transcripts,  enabled us  to  cover  all  COSMIC  annotated  mutations  in the 
selected exons of the target genes. The amplicon design covering 8 kb of genomic DNA was 
optimized for the simultaneous analysis of 8 samples (simultaneously DNA and RNA of the 
same patients) with the 316v2 chip (Thermofisher, Foster City, CA, USA) on a Personal 
Genome Machine Torrent (Thermofisher). The analytical sensitivity of the assay was assessed 
on DNA from cell lines. The experiments carried out on serial dilutions (10%; 5%; 1%) of 
mutated (BRAF V600E and RET – PTC1) cell lines derived nucleic acid showed an a limit of 
detection of 1% (data not reported) for both DNA and RNA NexThyro primers pool. As an 
explorative analysis, the clinical performance of NexThyro were assessed by using archival 
DNA and RNA from 16 patients, previously genotyped with a RT-PCR. The preliminary results 
obtained by using our custom NGS panel were satisfactory enough to expect, after an extensive 
clinical validation, its effective future adoption on our routine samples.  
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